Soligenix Inc. Targets Key Milestones in Rare Disease Pipeline with Upcoming Data Readouts

Soligenix Inc. (NASDAQ: SNGX), a biopharmaceutical company specializing in rare diseases, has provided a shareholder update detailing upcoming clinical and strategic milestones. The company's President and CEO, Dr. Christopher J. Schaber, emphasized the importance of forthcoming data readouts for its lead candidates. Notably, Phase 3 FLASH 2 results for HyBryte(TM), a treatment for cutaneous T-cell lymphoma, are expected in the second half of 2026. Additionally, updates on treatments for psoriasis (SGX302) and Behçet’s Disease (SGX945) are anticipated in the third and fourth quarters of 2025.

An investigator-initiated study has already demonstrated promising results, with a 75% success rate at 18 weeks. Soligenix projects that HyBryte(TM) could achieve peak U.S. annual sales exceeding $90 million, with global opportunities across its pipeline surpassing $2 billion. The company, which currently holds approximately $7 million in cash, is actively seeking partnerships and mergers and acquisitions to extend its financial runway into the first quarter of 2026. This strategic planning is part of Soligenix's broader efforts to prepare for global regulatory filings and the potential commercialization of its therapies.

For more information on Soligenix's developments, visit https://ibn.fm/dQUKU.